{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:03:42Z","timestamp":1787497422078,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health and Social Protection"},{"name":"The Africa Centres for Disease Control and Prevention"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50330-7","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:15:53Z","timestamp":1777025753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term kinetics of anti-RBD IgG antibodies 16 months after COVID-19 vaccination in Morocco: a longitudinal cohort study"],"prefix":"10.1038","volume":"16","author":[{"given":"Islam","family":"Abbadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2019hammed","family":"Sarih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Majidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad","family":"Redwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Batcho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Abounouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Aqillouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima","family":"Bouddahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soufiane","family":"Hilmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Ainahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raji","family":"Tajudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosoka Papa","family":"Fallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kaseya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahmane","family":"Maaroufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayeh","family":"Ezzikouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"50330_CR1","first-page":"1","volume":"2020","author":"S Maital","year":"2020","unstructured":"Maital, S. & Barzani, E. The global economic impact of COVID-19: A summary of research. Journal 2020, 1\u201312 (2020). https:\/\/www.neaman.org.il\/en\/the-global-economic-impact-of-covid-19-a-summary-of-research\/","journal-title":"Journal"},{"key":"50330_CR2","unstructured":"W.H.O. WHO Covid-19 dashboard: Covid-19 Cases, world (Access Date: https:\/\/data.who.int\/dashboards\/covid19\/cases?m49=001&n=c"},{"key":"50330_CR3","unstructured":"W.H.O. COVID-19 dashboard: COVID-19 Cases, Morocco. (Access Date: 20 August 2025). https:\/\/data.who.int\/dashboards\/covid19\/cases?m49=504&n=c"},{"key":"50330_CR4","unstructured":"W.H.O. COVID-19 vaccination, World data. (Access Date: 20 August 2025). https:\/\/data.who.int\/dashboards\/covid19\/vaccines?n=c"},{"key":"50330_CR5","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1002\/jmv.27214","volume":"93","author":"K Al","year":"2021","unstructured":"Al, K. et al. Safety of COVID-19 vaccines. J. J. Med. Virol. 93, 6588\u20136594. https:\/\/doi.org\/10.1002\/jmv.27214 (2021).","journal-title":"J. J. Med. Virol."},{"key":"50330_CR6","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1038\/s41598-024-58498-6","volume":"14","author":"S Ezzikouri","year":"2024","unstructured":"Ezzikouri, S. et al. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco. Sci. Rep. 14, 7817. https:\/\/doi.org\/10.1038\/s41598-024-58498-6 (2024).","journal-title":"Sci. Rep."},{"key":"50330_CR7","doi-asserted-by":"crossref","unstructured":"Loo, K. Y. et al. COVID-19: Insights into potential vaccines. Microorganisms.15;9(3):605. https:\/\/doi.org\/10.3390\/microorganisms9030605 (2021).","DOI":"10.3390\/microorganisms9030605"},{"key":"50330_CR8","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1186\/s12889-022-14016-9","volume":"22","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public. Health. 22, 1584. https:\/\/doi.org\/10.1186\/s12889-022-14016-9 (2022).","journal-title":"BMC Public. Health"},{"key":"50330_CR9","doi-asserted-by":"publisher","first-page":"11467","DOI":"10.1038\/s41598-024-61922-6","volume":"14","author":"MA Haq","year":"2024","unstructured":"Haq, M. A. et al. Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh. Sci. Rep. 14, 11467. https:\/\/doi.org\/10.1038\/s41598-024-61922-6 (2024).","journal-title":"Sci. Rep."},{"key":"50330_CR10","doi-asserted-by":"publisher","unstructured":"Gil-Manso, S. et al. IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study. Frontiers in Cellular and Infection Microbiology Volume 12\u2013 (2022). https:\/\/doi.org\/10.3389\/fcimb.2022.1035155. (2022).","DOI":"10.3389\/fcimb.2022.1035155"},{"key":"50330_CR11","doi-asserted-by":"publisher","first-page":"e0288557","DOI":"10.1371\/journal.pone.0288557","volume":"18","author":"H Amellal","year":"2023","unstructured":"Amellal, H. et al. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study. PLoS One. 18, e0288557. https:\/\/doi.org\/10.1371\/journal.pone.0288557 (2023).","journal-title":"PLoS One"},{"key":"50330_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119. https:\/\/doi.org\/10.1038\/s41586-020-2380-z (2020).","journal-title":"Nature"},{"key":"50330_CR13","doi-asserted-by":"publisher","first-page":"e2231778","DOI":"10.1001\/jamanetworkopen.2022.31778","volume":"5","author":"M Gilboa","year":"2022","unstructured":"Gilboa, M. et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection. JAMA Netw. Open. 5, e2231778\u2013e2231778. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31778 (2022).","journal-title":"JAMA Netw. Open."},{"key":"50330_CR14","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1186\/s12879-024-10345-9","volume":"24","author":"K Abounouh","year":"2024","unstructured":"Abounouh, K. et al. Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: A cross-sectional study in morocco. BMC Infect. Dis. 24, 1470. https:\/\/doi.org\/10.1186\/s12879-024-10345-9 (2024).","journal-title":"BMC Infect. Dis."},{"key":"50330_CR15","doi-asserted-by":"publisher","unstructured":"Livieratos, A., Gogos, C. & Akinosoglou, K. Impact of prior COVID-19 immunization and\/or prior infection on immune responses and clinical outcomes. Viruses 16 https:\/\/doi.org\/10.3390\/v16050685 (2024).","DOI":"10.3390\/v16050685"},{"key":"50330_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350. https:\/\/doi.org\/10.1126\/science.abm3425 (2022).","journal-title":"Science"},{"key":"50330_CR17","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.063 (2021).","journal-title":"Vaccine"},{"key":"50330_CR18","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: A meta-analysis. Lancet Microbe. 3, e52\u2013e61. https:\/\/doi.org\/10.1016\/S2666-5247(21)00267-6 (2022).","journal-title":"Lancet Microbe"},{"key":"50330_CR19","doi-asserted-by":"publisher","unstructured":"Assaid, N. et al. Anti-SARS-CoV-2 antibody responses 5 months post complete vaccination of Moroccan healthcare workers. Vaccines. https:\/\/doi.org\/10.3390\/vaccines10030465 (2022).","DOI":"10.3390\/vaccines10030465"},{"key":"50330_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4269\/ajtmh.22-0448","volume":"108","author":"N Assaid","year":"2023","unstructured":"Assaid, N. et al. Kinetics of SARS-CoV-2 IgM and IgG antibodies 3 months after COVID-19 Onset in Moroccan patients. Am. J. Trop. Med. Hyg. 108, 145\u2013154. https:\/\/doi.org\/10.4269\/ajtmh.22-0448 (2023).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"50330_CR21","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.jvacx.2023.100288","volume":"14","author":"H Amellal","year":"2023","unstructured":"Amellal, H. et al. Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers. Vaccine: X. 14, 100288. https:\/\/doi.org\/10.1016\/j.jvacx.2023.100288 (2023).","journal-title":"Vaccine: X"},{"key":"50330_CR22","doi-asserted-by":"publisher","first-page":"e0028821","DOI":"10.1128\/jcm.00288-21","volume":"59","author":"E English","year":"2021","unstructured":"English, E. et al. Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new variants of concern, VOC 202012\/V1 (United Kingdom) and VOC 202012\/V2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods. J. Clin. Microbiol. 59, e0028821. https:\/\/doi.org\/10.1128\/jcm.00288-21 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"50330_CR23","doi-asserted-by":"publisher","unstructured":"Najimi, N. et al. Seroprevalence and persistence of humoral immunity in response to SARS-CoV-2 vaccination and mild infection in Morocco: A cross-sectional study. Pan Afr. Med. J. 51, 53. https:\/\/doi.org\/10.11604\/pamj.2025.51.53.46802 (2025).","DOI":"10.11604\/pamj.2025.51.53.46802"},{"key":"50330_CR24","doi-asserted-by":"publisher","first-page":"126464","DOI":"10.1016\/j.vaccine.2024.126464","volume":"42","author":"A Harrache","year":"2024","unstructured":"Harrache, A. et al. Anti-RBD IgG dynamics following infection or vaccination. Vaccine 42, 126464. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126464 (2024).","journal-title":"Vaccine"},{"key":"50330_CR25","doi-asserted-by":"publisher","unstructured":"Yamamoto, S. et al. Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine. Clin. Microbiol. Infect. 29 https:\/\/doi.org\/10.1016\/j.cmi.2023.05.020 (2023).","DOI":"10.1016\/j.cmi.2023.05.020"},{"key":"50330_CR26","doi-asserted-by":"publisher","unstructured":"Yorsaeng, R. et al. SARS-CoV-2 Antibody dynamics after COVID-19 vaccination and infection: A real-world cross-sectional analysis. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines11071184 (2023).","DOI":"10.3390\/vaccines11071184"},{"key":"50330_CR27","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","volume":"28","author":"J Wei","year":"2022","unstructured":"Wei, J. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 28, 1072\u20131082. https:\/\/doi.org\/10.1038\/s41591-022-01721-6 (2022).","journal-title":"Nat. Med."},{"key":"50330_CR28","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1016\/j.vaccine.2022.07.023","volume":"40","author":"F Rammauro","year":"2022","unstructured":"Rammauro, F. et al. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. Vaccine 40, 5189\u20135196. https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.023 (2022).","journal-title":"Vaccine"},{"key":"50330_CR29","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"G Levin Einav","year":"2021","unstructured":"Levin Einav, G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84. https:\/\/doi.org\/10.1056\/NEJMoa2114583 (2021).","journal-title":"N. Engl. J. Med."},{"key":"50330_CR30","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829. https:\/\/doi.org\/10.1126\/science.abm0829 (2021).","journal-title":"Science"},{"key":"50330_CR31","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.immuni.2021.09.011","volume":"54","author":"A Sokal","year":"2021","unstructured":"Sokal, A. et al. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 54, 2893\u20132907e5. https:\/\/doi.org\/10.1016\/j.immuni.2021.09.011 (2021).","journal-title":"Immunity"},{"key":"50330_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109\u2013113. https:\/\/doi.org\/10.1038\/s41586-021-03738-2 (2021).","journal-title":"Nature"},{"key":"50330_CR33","doi-asserted-by":"publisher","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371 https:\/\/doi.org\/10.1126\/science.abf4063 (2021).","DOI":"10.1126\/science.abf4063"},{"key":"50330_CR34","doi-asserted-by":"publisher","first-page":"1455334","DOI":"10.3389\/fimmu.2024.1455334","volume":"15","author":"K Kometani","year":"2024","unstructured":"Kometani, K. et al. Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults. Front. Immunol. 15, 1455334. https:\/\/doi.org\/10.3389\/fimmu.2024.1455334 (2024).","journal-title":"Front. Immunol."},{"key":"50330_CR35","doi-asserted-by":"publisher","unstructured":"Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination. Sci. Immunol. 6 https:\/\/doi.org\/10.1126\/sciimmunol.abi6950 (2021).","DOI":"10.1126\/sciimmunol.abi6950"},{"key":"50330_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.anai.2022.10.003","volume":"130","author":"SM Ailsworth","year":"2023","unstructured":"Ailsworth, S. M. et al. Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273. Ann. Allergy Asthma Immunol. 130, 67\u201373. https:\/\/doi.org\/10.1016\/j.anai.2022.10.003 (2023).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"50330_CR37","doi-asserted-by":"publisher","first-page":"102676","DOI":"10.1016\/j.jiph.2025.102676","volume":"18","author":"F Ashrafian","year":"2025","unstructured":"Ashrafian, F. et al. Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses. J. Infect. Public Health. 18, 102676. https:\/\/doi.org\/10.1016\/j.jiph.2025.102676 (2025).","journal-title":"J. Infect. Public Health"},{"key":"50330_CR38","doi-asserted-by":"publisher","first-page":"e27211","DOI":"10.1016\/j.heliyon.2024.e27211","volume":"10","author":"MJ Choi","year":"2024","unstructured":"Choi, M. J. et al. Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy. Heliyon 10, e27211. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27211 (2024). https:\/\/doi.org\/.","journal-title":"Heliyon"},{"key":"50330_CR39","doi-asserted-by":"publisher","first-page":"30743","DOI":"10.1038\/s41598-024-80465-4","volume":"14","author":"ZJ Madewell","year":"2024","unstructured":"Madewell, Z. J. et al. Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico. Sci. Rep. 14, 30743. https:\/\/doi.org\/10.1038\/s41598-024-80465-4 (2024).","journal-title":"Sci. Rep."},{"key":"50330_CR40","doi-asserted-by":"publisher","unstructured":"Ciccone, E. J. et al. Oxford University Press US,. Magnitude and durability of the antibody response to mRNA-based vaccination among SARS-CoV-2 seronegative and seropositive health care personnel. in Open Forum Infectious Diseases11 ofae009. https:\/\/doi.org\/10.1093\/ofid\/ofae009 (2024).","DOI":"10.1093\/ofid\/ofae009"},{"key":"50330_CR41","doi-asserted-by":"publisher","unstructured":"Ben Hamouda, W. et al. A longitudinal study in tunisia to assess the anti-RBD IgG and IgA responses induced by three different COVID-19 vaccine platforms. Trop. Med. Infect. 9(3), 61. https:\/\/doi.org\/10.3390\/tropicalmed9030061 (2024).","DOI":"10.3390\/tropicalmed9030061"},{"key":"50330_CR42","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1093\/cid\/ciaf095","volume":"80","author":"RM Chissumba","year":"2025","unstructured":"Chissumba, R. M. et al. Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine. Clin. Infect. Dis. 80, S57\u2013s65. https:\/\/doi.org\/10.1093\/cid\/ciaf095 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"50330_CR43","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","volume":"54","author":"F Muecksch","year":"2021","unstructured":"Muecksch, F. et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 54, 1853\u20131868. https:\/\/doi.org\/10.1016\/j.immuni.2021.07.008 (2021). .e7.","journal-title":"Immunity"},{"key":"50330_CR44","doi-asserted-by":"publisher","unstructured":"Zimmermann, P. & Curtis, N. Factors that influence the immune response to vaccination. Clin. Microbiol. Rev. 32 https:\/\/doi.org\/10.1128\/cmr.00084-18 (2019).","DOI":"10.1128\/cmr.00084-18"},{"key":"50330_CR45","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1016\/j.vaccine.2017.07.062","volume":"36","author":"GA Poland","year":"2018","unstructured":"Poland, G. A., Ovsyannikova, I. G. & Kennedy, R. B. Personalized vaccinology: A review. Vaccine 36, 5350\u20135357. https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.062 (2018).","journal-title":"Vaccine"},{"key":"50330_CR46","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/all.15652","volume":"6","author":"D Brigger","year":"2023","unstructured":"Brigger, D. et al. Sex-specific differences in immune response to SARS-CoV-2 vaccination vanish with age. Allergy 6, 1683\u20131686. https:\/\/doi.org\/10.1111\/all.15652 (2023).","journal-title":"Allergy"},{"key":"50330_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40520-025-02990-0","volume":"37","author":"OA Oyebanji","year":"2025","unstructured":"Oyebanji, O. A. et al. COVID-19 booster doses reduce sex disparities in antibody responses among nursing home residents. Aging Clin. Exp. Res. 37, 73. https:\/\/doi.org\/10.1007\/s40520-025-02990-0 (2025).","journal-title":"Aging Clin. Exp. Res."},{"key":"50330_CR48","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.vaccine.2022.01.002","volume":"40","author":"Y Uwamino","year":"2022","unstructured":"Uwamino, Y. et al. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff. Vaccine 40, 1019\u20131025. https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.002 (2022).","journal-title":"Vaccine"},{"key":"50330_CR49","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85051","author":"K Badruddza","year":"2025","unstructured":"Badruddza, K., Habib, S., Rahman, S. N., Hossain, S. & Mollah, F. H. Comparative analysis of anti-receptor binding domain (RBD) IgG responses to homologous and heterologous SARS-CoV-2 vaccine regimens: A study from Bangladesh. Cureus https:\/\/doi.org\/10.7759\/cureus.85051 (2025).","journal-title":"Cureus"},{"key":"50330_CR50","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41467-022-28527-x","volume":"13","author":"H Ward","year":"2022","unstructured":"Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 13, 907. https:\/\/doi.org\/10.1038\/s41467-022-28527-x (2022).","journal-title":"Nat. Commun."},{"key":"50330_CR51","doi-asserted-by":"publisher","unstructured":"Shapiro, J. R. et al. Association of frailty, age, and biological sex with severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine\u2013induced immunity in older adults. Clin. Infect. Dis. 75, S61\u2013S71. https:\/\/doi.org\/10.1093\/cid\/ciac397 (2022).","DOI":"10.1093\/cid\/ciac397"},{"key":"50330_CR52","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1038\/s41467-022-32312-1","volume":"13","author":"L Renia","year":"2022","unstructured":"Renia, L. et al. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nat. Commun. 13, 4615. https:\/\/doi.org\/10.1038\/s41467-022-32312-1 (2022).","journal-title":"Nat. Commun."},{"key":"50330_CR53","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41590-023-01508-y","volume":"24","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. Nat. Immunol. 24, 966\u2013978. https:\/\/doi.org\/10.1038\/s41590-023-01508-y (2023).","journal-title":"Nat. Immunol."},{"key":"50330_CR54","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/s41591-023-02414-4","volume":"29","author":"E Barnes","year":"2023","unstructured":"Barnes, E. et al. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nat. Med. 29, 1760\u20131774. https:\/\/doi.org\/10.1038\/s41591-023-02414-4 (2023).","journal-title":"Nat. Med."},{"key":"50330_CR55","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","volume":"27","author":"RT Shroff","year":"2021","unstructured":"Shroff, R. T. et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat. Med. 27, 2002\u20132011. https:\/\/doi.org\/10.1038\/s41591-021-01542-z (2021).","journal-title":"Nat. Med."},{"key":"50330_CR56","doi-asserted-by":"publisher","first-page":"126121","DOI":"10.1016\/j.vaccine.2024.07.022","volume":"42","author":"CE Hoeve","year":"2024","unstructured":"Hoeve, C. E. et al. COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study. Vaccine 42, 126121. https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.022 (2024).","journal-title":"Vaccine"},{"key":"50330_CR57","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12979-024-00476-7","volume":"21","author":"Y Kuijpers","year":"2024","unstructured":"Kuijpers, Y. et al. Health characteristics associated with persistence of SARS-CoV-2 antibody responses after repeated vaccinations in older persons over time: the Doetinchem cohort study. Immun. Ageing. 21, 68. https:\/\/doi.org\/10.1186\/s12979-024-00476-7 (2024).","journal-title":"Immun. Ageing"},{"key":"50330_CR58","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417\u2013422. https:\/\/doi.org\/10.1038\/s41586-021-03739-1 (2021).","journal-title":"Nature"},{"key":"50330_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41541-025-01268-w","volume":"10","author":"RA Purcell","year":"2025","unstructured":"Purcell, R. A. et al. Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination. NPJ Vaccines. 10, 217. https:\/\/doi.org\/10.1038\/s41541-025-01268-w (2025).","journal-title":"NPJ Vaccines"},{"key":"50330_CR60","doi-asserted-by":"publisher","first-page":"8426","DOI":"10.1038\/s41598-024-58811-3","volume":"14","author":"CS Korosec","year":"2024","unstructured":"Korosec, C. S., Dick, D. W., Moyles, I. R. & Watmough, J. SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series. Sci. Rep. 14, 8426. https:\/\/doi.org\/10.1038\/s41598-024-58811-3 (2024).","journal-title":"Sci. Rep."},{"key":"50330_CR61","doi-asserted-by":"publisher","unstructured":"Ashrafian, F. et al. A comparative study of immunogenicity, antibody persistence, and safety of three different COVID-19 boosters between individuals with comorbidities and the normal population. Vaccines. https:\/\/doi.org\/10.3390\/vaccines11081376 (2023).","DOI":"10.3390\/vaccines11081376"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50330-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50330-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50330-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:33:27Z","timestamp":1781739207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50330-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50330"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50330-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"was obtained from all participants involved in the study. For minors, the informed consent of a parent has been obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study was approved by the ethics committee of Ibn Rochd hospital in Casablanca (N\u00b001\/22).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"18954"}}